目的 探讨五味苦参肠溶胶囊联合奥沙拉秦钠胶囊治疗溃疡性结肠炎的疗效。方法 将2023年7月—2025年6月湖南中医药大学第一附属医院收治的85例溃疡性结肠炎患者作为研究对象，按随机数字表法将患者分对照组（42例）和治疗组（43例）。对照组患者口服奥沙拉秦钠胶囊，2粒/次，2次/d。治疗组在对照组基础上口服五味苦参肠溶胶囊，4粒/次，3次/d。两组持续治疗6周。比较两组患者的临床疗效、症状消失时间、疾病活动度、生活质量、血清指标。结果 治疗后，治疗组的总有效率为95.35%，对照组的总有效率为80.95%，组间比较差异显著（P＜0.05）。治疗组患者腹痛、腹泻、便血、里急后重感消失时间明显短于对照组（P＜0.05）。两组治疗后的Mayo评分显著降低，炎症性肠病生活质量问卷（IBDQ）评分明显升高（P＜0.05）；治疗组治疗后Mayo评分明显低于对照组，IBDQ评分明显高于对照组（P＜0.05）。两组治疗后血清低氧诱导因子-1α（HIF-1α）、胰岛素样生长因子1（IGF-1）、人趋化素（chemerin）水平均降低（P＜0.05）；治疗组治疗后血清HIF-1α、IGF-1、chemerin水平均低于对照组（P＜0.05）。结论 五味苦参肠溶胶囊联合奥沙拉秦钠胶囊可提高溃疡性结肠炎的临床疗效，改善临床症状，降低疾病活动度，提高生活质量，机制与减轻炎症反应有关。

Objective To investigate the efficacy of Wuwei Kushen Colon-Coated Capsules combined with Olsalazine Sodium Capsules in treatment of ulcerative colitis. Methods 85 Patients with ulcerative colitis admitted to the First Affiliated Hospital of Hunan University of Traditional Chinese Medicine from July 2023 to June 2025 were selected as the research subjects. Patients were divided into control group (42 cases) and treatment group (43 cases) using a random number table method. Patients in the control group took orally Oxalazine Sodium Capsules, 2 capsules/time, twice daily. Patients in the treatment group took orally Wuwei Kushen Colon-Coated Capsules on the base of the control group, 4 capsules/time, 3 times daily. Two groups continued treatment for 6 weeks. The clinical efficacy, symptom disappearance time, disease activity, quality of life, and serum indicators were compared between two groups of patients. Results After treatment, the total effective rate of the treatment group was 95.35%, while the total effective rate of the control group was 80.95%, with a significant difference between two groups (P < 0.05). The disappearance time of abdominal pain, diarrhea, rectal bleeding, and urgency in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the Mayo score significantly decreased in two groups, but the Inflammatory Bowel Disease Quality of Life Questionnaire (IBDQ) score significantly increased (P < 0.05). After treatment, the Mayo score of the treatment group was significantly lower than that of the control group, but the IBDQ score was significantly higher than that of the control group (P < 0.05). After treatment, the serum levels of hypoxia inducible factor-1α (HIF-1α), insulin-like growth factor-1 (IGF-1), and chemokine (chemerin) decreased in the two groups (P < 0.05). The serum levels of HIF-1α, IGF-1, and chemerin in the treatment group were lower than those in the control group after treatment (P < 0.05). Conclusion The combination of Wuwei Kushen Colon-Coated Capsules and Olsalazine Sodium Capsules can improve the clinical efficacy of ulcerative colitis, alleviate clinical symptoms, reduce disease activity, and enhance quality of life. The mechanism is related to reducing inflammatory response.

R975

湖南省卫生计生委科研计划课题项目（C20180627）